Literature DB >> 33184474

Effects of substance misuse on reward-processing in patients with attention-deficit/hyperactivity disorder.

Maria Paraskevopoulou1,2, Daan van Rooij3, Albert Batalla4, Roselyne Chauvin3, Maartje Luijten5, Aart H Schene6,7, Jan K Buitelaar7,8, Arnt F A Schellekens6,9.   

Abstract

Attention-Deficit/Hyperactivity Disorder (ADHD) and Substance Use Disorder (SUD) often co-occur and are associated with treatment resistance. Both disorders are characterized by similar reward-processing deficits with decreased striatal responses to reward anticipation, though literature is inconsistent. It is unclear whether substance misuse exaggerates reward-processing deficits observed in ADHD. The aim of this study was to examine substance misuse effects on reward-processing in ADHD. Functional MRI data in a Monetary Incentive Delay (MID) task from a multi-site study were compared across ADHD groups with and without substance misuse (ADHD + SM and ADHD-only, respectively) and healthy controls (n = 40/group, 74 males and 46 females, aged 13.7-25.9 years). Substance misuse was defined as misuse of alcohol, nicotine, or drugs. Groups were matched with presence/absence of parental SUD to avoid interference with SUD trait effects. Compared to ADHD-only and controls, ADHD + SM showed hyperactivation in putamen during reward anticipation. Compared to controls, the ADHD groups showed hypoactivation in motor/sensory cortices and hyperactivation in frontal pole and OFC during reward outcome. ADHD + SM also showed hyperactivation in frontal pole during neutral outcome. Moreover, ADHD + SM patients showed higher callous-unemotional (CU) traits that were positively correlated with putamen responses to reward anticipation. Our results show distinct condition-independent neural activation profile for ADHD + SM compared to ADHD-only and controls. Effects of comorbid substance misuse and variability of its prevalence across ADHD studies might have contributed to inconsistencies in ADHD literature. Contrasted with findings for reward-processing in SUD literature, results potentially suggest distinct underlying mechanisms for SUD subgroups with different characteristics, like antisocial/psychopathic traits.

Entities:  

Mesh:

Year:  2020        PMID: 33184474      PMCID: PMC8027205          DOI: 10.1038/s41386-020-00896-1

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  54 in total

1.  Impulsivity and rapid discounting of delayed hypothetical rewards in cocaine-dependent individuals.

Authors:  Scott F Coffey; Gregory D Gudleski; Michael E Saladin; Kathleen T Brady
Journal:  Exp Clin Psychopharmacol       Date:  2003-02       Impact factor: 3.157

2.  Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis.

Authors:  Xavier Castells; Josep Antoni Ramos-Quiroga; David Rigau; Rosa Bosch; Mariana Nogueira; Xavier Vidal; Miguel Casas
Journal:  CNS Drugs       Date:  2011-02       Impact factor: 5.749

Review 3.  The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies.

Authors:  Stephen V Faraone; Joseph Biederman; Eric Mick
Journal:  Psychol Med       Date:  2006-02       Impact factor: 7.723

Review 4.  Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: a meta-analytic review.

Authors:  Steve S Lee; Kathryn L Humphreys; Kate Flory; Rebecca Liu; Kerrie Glass
Journal:  Clin Psychol Rev       Date:  2011-01-20

Review 5.  Attention-deficit/hyperactivity disorder and risk of substance use disorder: developmental considerations, potential pathways, and opportunities for research.

Authors:  Brooke S G Molina; William E Pelham
Journal:  Annu Rev Clin Psychol       Date:  2014-01-15       Impact factor: 18.561

6.  Treatment seeking adults with autism or ADHD and co-morbid substance use disorder: prevalence, risk factors and functional disability.

Authors:  Bram Sizoo; Wim van den Brink; Maarten Koeter; Marielle Gorissen van Eenige; Patricia van Wijngaarden-Cremers; Rutger Jan van der Gaag
Journal:  Drug Alcohol Depend       Date:  2009-09-27       Impact factor: 4.492

Review 7.  Attention-deficit/hyperactivity disorder.

Authors:  Stephen V Faraone; Philip Asherson; Tobias Banaschewski; Joseph Biederman; Jan K Buitelaar; Josep Antoni Ramos-Quiroga; Luis Augusto Rohde; Edmund J S Sonuga-Barke; Rosemary Tannock; Barbara Franke
Journal:  Nat Rev Dis Primers       Date:  2015-08-06       Impact factor: 52.329

Review 8.  Epidemiology of attention-deficit/hyperactivity disorder across the lifespan.

Authors:  Guilherme Polanczyk; Luis Augusto Rohde
Journal:  Curr Opin Psychiatry       Date:  2007-07       Impact factor: 4.741

Review 9.  Impact of ADHD and its treatment on substance abuse in adults.

Authors:  Timothy E Wilens
Journal:  J Clin Psychiatry       Date:  2004       Impact factor: 4.384

10.  Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity.

Authors:  J Biederman; T Wilens; E Mick; S Milberger; T J Spencer; S V Faraone
Journal:  Am J Psychiatry       Date:  1995-11       Impact factor: 18.112

View more
  3 in total

Review 1.  Neurobehavioral maturation of motor response inhibition in adolescence - A narrative review.

Authors:  Hannah Weiss; Monica Luciana
Journal:  Neurosci Biobehav Rev       Date:  2022-03-30       Impact factor: 9.052

2.  Altered single-subject gray matter structural networks in drug-naïve attention deficit hyperactivity disorder children.

Authors:  Ying Chen; Du Lei; Hengyi Cao; Running Niu; Fuqin Chen; Lizhou Chen; Jinbo Zhou; Xinyu Hu; Xiaoqi Huang; Lanting Guo; John A Sweeney; Qiyong Gong
Journal:  Hum Brain Mapp       Date:  2021-11-19       Impact factor: 5.038

3.  Effects of substance misuse on inhibitory control in patients with attention-deficit/hyperactivity disorder.

Authors:  Maria Paraskevopoulou; Daan van Rooij; Aart H Schene; Roselyne Chauvin; Jan K Buitelaar; Arnt F A Schellekens
Journal:  Addict Biol       Date:  2021-06-07       Impact factor: 4.093

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.